F-18-fluciclovine PET helps detect and localize recurrent prostate cancer allowing for individualized, targeted therapy.
A single 19-Gy fraction of brachytherapy was found as effective as a longer regimen of low-dose-rate brachytherapy in localized prostate cancer.
Cabozantinib activated innate immunity and completely eradicated prostate cancer in a study using a mouse model.
Shorter course of higher dose radiation therapy provide effective treatment, costs less, and is easier on patients than current standard radiation therapy course.
There is no association between vasectomy and the risk of overall, high-grade, or advanced-stage prostate cancer or prostate cancer-related mortality.
A lower dose of abiraterone acetate with a low fat meal may have the same effect as taking the standard dose as recommended on an empty stomach.
Treatment expectations of individuals with metastatic prostate cancer and their health care providers often do not match.
African American men choosing active surveillance for their low-grade prostate cancer have overall poorer health than non-African American men undergoing active surveillance.
Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net HospitalsFebruary 24, 2017
A significant difference exists in the failure to follow-up rates among patients undergoing active surveillance at university-based hospitals versus safety-net hospitals.
The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.
A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.
Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.
A higher overall number of genetic alterations in cell-free circulating tumor DNA (ctDNA) were associated with worse treatment outcomes.
Investigators studied the effects of adding antiandrogen therapy to radiotherapy on cancer control and overall survival in men with prostate cancer recurrence after radical prostatectomy.
Clinicians May Want To Address Emotional Stress to Prevent Overtreatment of Localized Prostate CancerJanuary 30, 2017
Some men with low-risk prostate cancer may opt for more aggressive treatments due to emotional distress.
The implementation of recommendations opposing regular prostate cancer screening appear to have lowered treatment rates dramatically.
Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.
This fact reviews how hormone therapy may be used to treat prostate cancer, treatment options for castration-resistant prostate cancer, and side effects of hormone therapy.
Patients on active surveillance with stable disease may be candidates for less intense surveillance
Although many men obtain a second opinion regarding their prostate cancer care options, they seldom deviate from the original course of action.
Magnetic resonance imaging and MRI-targeted biopsy can facilitate detection of clinically significant prostate disease.
Advanced prostate cancer is associated with substantial psychosocial morbidity; therefore, this study was conducted to evaluate whether mindfulness-based cognitive therapy reduces distress in this population.
Consensus statement presents guidelines for prostate magnetic resonance imaging (MRI) in patients with negative biopsy.
Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate CancerNovember 18, 2016
[Clinical Medicine Insights: Oncology] This research examines the various mechanisms of resistance to chemotherapy in metastatic CRPC and the potential role of emerging regimens and agents in varying clinical phases of development.
Studies show better physical function and quality of life for cancer patients who do strength training or aerobic activity.
The impact of additional opinions on patient decision-making is limited.
Researchers report on their evaluation of the impact of the 2012 USPSTF recommendation on volumes of prostate biopsy and radical prostatectomy.
Researchers analyzed data from the NPCR of Sweden to determine whether more US men with prostate cancer would choose active surveillance if it were presented as a treatment option.
Growing evidence suggests a link between androgen deprivation therapy (ADT) and cognitive dysfunction, but whether it may contribute to the risk of dementia more broadly is unclear. In this study, researchers examined the association of ADT with subsequent development of dementia in patients with prostate cancer.
Radiotherapy administered postoperatively within 1 year of radical prostatectomy was associated with worse functional outcomes compared with radiotherapy administered 1 year or more after surgery.
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|